Abstracts tagged "Biomarkers"

Abstract Number: 2016 • ACR Convergence 2020
Baseline Serum Biomarker Levels Predict Spinal Radiographic Progression in Ankylosing Spondylitis Patients on TNF Inhibitor Therapy
Judith Rademacher¹, Mark Siderius², Laura Gellert¹, Freke Wink³, Maryna Verba¹, Fiona Maas⁴, Lorraine M Tietz¹, Denis Poddubnyy⁵, Anneke Spoorenberg³ and Suzanne Arends³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands, ⁴University medical Centre Groningen, Groningen, Netherlands, ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Radiographic spinal progression determinates functional status and mobility in ankylosing spondylitis (AS) (Poddubnyy et al, 2018). Our objective was to analyze whether biomarker levels…
Abstract Number: 0037 • ACR Convergence 2020
Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome
Adrianos Nezos¹, Eleni Kotsifaki¹, Charalampos Skarlis², Konstantinos Markakis¹, Haralampos Moutsopoulos³, Michael Koutsilieris¹, Clio Mavragani¹ and Anna Psarrou¹, ¹National & Kapodistrian University of Athens, Athens, Greece, ²National &Kapodistrian University of Athens, Athens, Greece, ³National & Kapodistrian University of Athens/ Academy of Athens, Athens, Greece
Background/Purpose: B-cell non-Hodgkin's lymphoma (B-NHL) is one of the major complications of primary Sjögren’s syndrome (SS). Chronic inflammation and macrophages in SS minor salivary glands…
Abstract Number: 0503 • ACR Convergence 2020
Targeted Metabolomic Profiling and Prediction of Cardiovascular Events: A Prospective Study of Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis and psoriasis, collectively termed psoriatic disease (PsD), are associated with increased cardiovascular (CV) risk. Metabolites comprise biomarkers that may add predictive value…
Abstract Number: 0764 • ACR Convergence 2020
Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data
Dmitry Rychkov¹, Jessica Neely¹ and Marina Sirota¹, ¹UCSF, San Francisco, CA
Background/Purpose: There is an urgent need to develop objective biomarkers for early diagnosis and monitoring of disease activity in Rheumatoid arthritis (RA). Here we define…
Abstract Number: 1114 • ACR Convergence 2020
Longitudinally Assessed Structural Abnormalities on MRI and Relative Contributions to Risk of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up
C. Kent Kwoh¹, Ali Guermazi², Erin Ashbeck³, Chengcheng Hu³, Edward Bedrick³, Leena Sharma⁴, Charles Eaton⁵, Marc Hochberg⁶, Rebecca Jackson⁷, Timothy McAlindon⁸, Michael Nevitt⁹, Jane Cauley¹⁰ and Frank Roemer¹¹, ¹University of Arizona of Arizona Arthritis Center and Division of Rheumatology, College of Medicine, University of Arizona, Tucson, AZ, ²Boston University School of Medicine, Boston, MA, ³University of Arizona, Tucson, AZ, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Department of Family Medicine and Epidemiology, Warren Alpert Medical School of Brown University,Department of Epidemiology, School of Public Health of Brown University, Providence, RI, ⁶University of Maryland School of Medicine, Baltimore, MD, ⁷Ohio State University, Columbus, OH, ⁸Tufts Medical Center, Boston, MA, ⁹University of California, San Francisco, San Francisco, CA, ¹⁰University of Pittsburgh, Pittsburgh, PA, ¹¹Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: MRI has identified joint tissues affected during knee OA development, though the relative importance of structures in the pathogenic process is unknown. Our objective…
Abstract Number: 1233 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
Jonathan Kay¹, Amy Bock², Noriko Iikuni³, Wuyan Zhang⁴ and Daniel Alvarez⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Cambridge, MA, ³Pfizer, New York, NY, ⁴Pfizer, New York, ⁵Pfizer, Collegeville, PA
Background/Purpose: Traditional efficacy endpoints of disease activity (DA) in studies of anti-rheumatic drugs can be confounded by subjective (patient-/physician-reported) assessments, comorbidities, and pre-existing joint damage.…
Abstract Number: 1536 • ACR Convergence 2020
Ultrasound as an Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Early Rheumatoid Arthritis, TOVERA – a Longitudinal Study
Maria S. Stoenoiu¹, Mihaela Maruseac², Mouna Messaoudi², Adrien Nzeusseu Toukap³ and Esperanza Naredo⁴, ¹1Department of Rheumatology, Cliniques Universitaires Saint-Luc, 2Institut de recherche expérimentale et cliniques (IREC), Brussels, Belgium, ²1Department of Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁴Department of Rheumatology, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, IIS Fundación Jiménez Díaz and Universidad Autónoma de Madrid, Madrid, Spain
Background/Purpose: The combination of methotrexate (MTX) and tocilizumab (TCZ) has been proven to be superior to MTX alone in early rheumatoid arthritis (RA)1 and was…
Abstract Number: 1808 • ACR Convergence 2020
Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)
Jill Buyon¹, John Conklin², Michael Golpanian¹, JoAnne Ligayon³, Thierry Dervieux⁴, Peter Izmirly¹, H. Michael Belmont¹, Jane Salmon⁵ and Roberta Vezza Alexander³, ¹New York University, New York, NY, ²Exagen Inc., Vista, CA, ³Exagen Inc, Vista, CA, ⁴Exagen Inc, San Diego, CA, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Despite improvement in management and outcomes of pregnancies complicated by SLE, the risk of adverse events and preeclampsia (PE) continues to exceed that of…
Abstract Number: 2034 • ACR Convergence 2020
Resolving Phenotypic and Prognostic Differences in Interstitial Lung Disease Related to Systemic Sclerosis by Computed Tomography-based Radiomics
Janine Schniering¹, Malgorzata Maciukiewicz¹, Hubert Gabrys², Matthias Brunner¹, Christian Blütghen³, Chantal Meier¹, Sophie Braga-Lagache⁴, Anne-Christine Ulgry⁴, Manfred Heller⁴, Oliver Distler¹, Matthias Guckenberger², Havard Fretheim⁵, Anna-Maria Hoffmann-Vold⁵, Christos Nakas⁶, Thomas Frauenfelder³, Stephanie Tanadini-Lang² and Britta Maurer⁷, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ²Department of Radiation Oncology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ³Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ⁴Proteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, Switzerland, Bern, Switzerland, ⁵Department of Rheumatology, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Norway, Oslo, Norway, ⁶Laboratory of Biometry, University of Thessaly, Volos, Greece, Volos, Greece, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich
Background/Purpose: Radiomics describes the in-depth analysis of tissue phenotypes by computational retrieval of high-dimensional quantitative imaging features including tissue intensity, texture, and wavelet characteristics. Here,…
Abstract Number: 014 • 2020 Pediatric Rheumatology Symposium
Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis
Dirk Foell¹, Carolin Park ², Linda Ziegler ², Dirk Holziner ³, Kirsten Minden ⁴, Renato Cotti ⁵ and Jakob Weber ⁵, ¹University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, ²University of Muenster, Muenster, Germany, ³University of Essen, Essen, Germany, ⁴Berlin, Germany, ⁵Buehlmann Laboratories, Schoenenbuch, Switzerland
Background/Purpose: Treat-to-target strategies are established for the therapeutic approach to patients suffering from juvenile idiopathic arthritis (JIA). Another proposed therapeutic concept in pediatric rheumatology involves…
Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium
Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis
Ryan Funk¹ and Mara Becker ², ¹University of Kansas, Leawood, Kansas, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill
Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
Abstract Number: 055 • 2020 Pediatric Rheumatology Symposium
Differential Analysis of Serum and Urine S100 Proteins in Juvenile-onset Systemic Lupus Erythematosus (jSLE)
Sean Donohue ¹, Angela Midgley ¹, Jennifer Davies ¹, Rachael Wright ¹, Ian Bruce ², Michael Beresford ¹ and Christian Hedrich¹, ¹University of Liverpool, Liverpool, United Kingdom, ²The University of Manchester, Manchester, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is a systemic autoimmune/inflammatory disease. Up to 80% of patients develop lupus nephritis (LN) that affects treatment and prognosis(1-3).…
Abstract Number: 079 • 2020 Pediatric Rheumatology Symposium
Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis
Arianna De Matteis ¹, Denise Pires Marafon ², Ivan Caiello ², Manuela Pardeo ², Giulia Marucci ², Emanuela Sacco ², Giusi Prencipe ², Fabrizio De Benedetti ² and Claudia Bracaglia², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Lazio, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm. Prompt recognition and early treatment are essential…
Abstract Number: 140 • 2020 Pediatric Rheumatology Symposium
Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade
Claas Hinze¹, Tanja Hinze ², Helmut Wittkowski ¹, Christoph Kessel ¹, Sabrina Fuehner ¹ and Dirk Foell ¹, ¹University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, ²Muenster, Nordrhein-Westfalen, Germany
Background/Purpose: Most, but not all, patients with systemic juvenile idiopathic arthritis (systemic JIA) respond to therapy with interleukin (IL)-1 blocking agents but predictive factors have…
Abstract Number: 156 • 2020 Pediatric Rheumatology Symposium
Metabolic Profiling in Juvenile Dermatomyositis
Jeffrey Dvergsten¹, Olga Ilkayeva ², Lawrence Landerman ², Michael Muehlbauer ³, David Pisetsky ⁴, Ann Reed ³ and Kim Huffman ⁵, ¹Duke University Hospital, Hillsborough, ²Duke University, Durham, NC, ³Duke University, Durham, ⁴Duke University Medical Center, Durham, ⁵Durham
Background/Purpose: Investigators have made significant progress piecing together pathogenic mechanisms of juvenile dermatomyositis (DM). However, this remains an incomplete puzzle, and optimal approaches to diagnosing,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].